European Society for Medical Oncology Asia Congress 2023

Description

+ Include: 325 videos + 237 pdfs, size: 27.4 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

+ Topics:

Advances in systemic and loco Hepatic arterial infusion- Enhancing response in neoadjuvant or salvage.mp4
Advances in systemic and loco Hepatic arterial infusion- Enhancing response in neoadjuvant or salvage.pdf
Advances in systemic and loco Local and locoregional treatments- An update on current options.mp4
Advances in systemic and loco Local and locoregional treatments- An update on current options.pdf
Advances in systemic and loco Q&A and discussion.mp4
An eye on the future Bispecific antibodies Early activity signals in gastrointestinal tumours.mp4
An eye on the future Bispecific antibodies Early activity signals in gastrointestinal tumours.pdf
An eye on the future Novel therapies for gastroesophageal cancer.mp4
An eye on the future Novel therapies for gastroesophageal cancer.pdf
An eye on the future Q&A and discussion.mp4
An eye on the future Targeted therapies in hepatobiliary cancers.mp4
An eye on the future Targeted therapies in hepatobiliary cancers.pdf
Astellas Biomarker testing in gastric cancer- Solving practical issues and surmounting challenges.mp4
Astellas Claudin as a therapeutic target in gastric cancer.mp4
Astellas Conclusion.mp4
Astellas Novel targeted therapy approaches in gastric cancer.mp4
Astellas Panel discussion on the challenges of the management of gastric cancer.mp4
Astellas Transformation of gastric cancer management in the past decade (from BSC to chemo to targeted + IO).mp4
Brain metastasis Q&A and discussion.mp4
Brain metastasis Radiation for brain metastases- Upfront, at progression or nothing at all.mp4
Brain metastasis Radiation for brain metastases- Upfront, at progression or nothing at all.pdf
Brain metastasis Standards and advances in the diagnosis and treatment of leptomeningeal disease.mp4
Brain metastasis Standards and advances in the diagnosis and treatment of leptomeningeal disease.pdf
Challenges in melanoma treatment Adjuvant treatment in high-risk stage II melanoma- Do we still need SLNB.mp4
Challenges in melanoma treatment Adjuvant treatment in high-risk stage II melanoma- Do we still need SLNB.pdf
Challenges in melanoma treatment Managing advanced acral and mucosal melanoma.mp4
Challenges in melanoma treatment Managing advanced acral and mucosal melanoma.pdf
Challenges in melanoma treatment Q&A and discussion.mp4
Collaborative session- Cellular therapies Cell-based therapies and the new EU Pharmaceutical Regulation proposal.mp4
Collaborative session- Cellular therapies Challenges in the development and regulatory approval of cell-based therapies in Asia.mp4
Collaborative session- Cellular therapies Challenges in the development and regulatory approval of cell-based therapies in Asia.pdf
Collaborative session- Cellular therapies Implementing cell-based therapies in reference centers and networks- Bottlenecks and opportunities.mp4
Collaborative session- Cellular therapies Implementing cell-based therapies in reference centers and networks- Bottlenecks and opportunities.pdf
Collaborative session- Cellular therapies Q&A and discussion.mp4
Collaborative session- Optimising drug Assessing the clinical value of new cancer therapeutics in real life settings- Tools and challenges.mp4
Collaborative session- Optimising drug Assessing the clinical value of new cancer therapeutics in real life settings- Tools and challenges.pdf
Collaborative session- Optimising drug Early phase oncology drug development in Asia Pacific.mp4
Collaborative session- Optimising drug Early phase oncology drug development in Asia Pacific.pdf
Collaborative session- Optimising drug Empowering networks and community hospitals for participation in cancer phase III trials.mp4
Collaborative session- Optimising drug Empowering networks and community hospitals for participation in cancer phase III trials.pdf
Collaborative session- Optimising drug Introduction.mp4
Collaborative session- Optimising drug Introduction.pdf
Collaborative session- Optimising drug Q&A and discussion.mp4
Collaborative session- Optimising drug The optimal positioning and use of platform trial designs in drug development in oncology.mp4
Collaborative session- Optimising drug The optimal positioning and use of platform trial designs in drug development in oncology.pdf
Collaborative session- The evolving screening Q&A and discussion.mp4
Collaborative session- The evolving screening Strategies of molecular profiling of hepato biliary cancers- Perceived value and ongoing research.mp4
Collaborative session- The evolving screening Strategies of molecular profiling of hepato biliary cancers- Perceived value and ongoing research.pdf
Collaborative session- The evolving screening Tackling survivorship issues in patients with hepato biliary cancers.mp4
Collaborative session- The evolving screening Tackling survivorship issues in patients with hepato biliary cancers.pdf
Demystifying the treatment of uterine leiomyosarcoma A case of early stage LMS that will recur as a single lesion 7 months later.mp4
Demystifying the treatment of uterine leiomyosarcoma A case of early stage LMS that will recur as a single lesion 7 months later.pdf
Demystifying the treatment of uterine leiomyosarcoma Defining the role of chemotherapy- When and which.mp4
Demystifying the treatment of uterine leiomyosarcoma Defining the role of chemotherapy- When and which.pdf
Demystifying the treatment of uterine leiomyosarcoma Is there hope from molecular therapies.mp4
Demystifying the treatment of uterine leiomyosarcoma Is there hope from molecular therapies.pdf
Demystifying the treatment of uterine leiomyosarcoma Q&A and discussion.mp4
Demystifying the treatment of uterine leiomyosarcoma Should all patients receive radiotherapy.mp4
Demystifying the treatment of uterine leiomyosarcoma Should all patients receive radiotherapy.pdf
Epidermal growth factor receptor Broader overview of screening in never smokers.mp4
Epidermal growth factor receptor Broader overview of screening in never smokers.pdf
Epidermal growth factor receptor Chemotherapy and immunotherpay- Any role to play at all.mp4
Epidermal growth factor receptor Chemotherapy and immunotherpay- Any role to play at all.pdf
Epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs)- Which one How long When.mp4
Epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs)- Which one How long When.pdf
Epidermal growth factor receptor Integrating radiation in early stage EGFR.mp4
Epidermal growth factor receptor Integrating radiation in early stage EGFR.pdf
Epidermal growth factor receptor Molecular testing minimal residual disease (MRD).mp4
Epidermal growth factor receptor Molecular testing minimal residual disease (MRD).pdf
Epidermal growth factor receptor Q&A and discussion.mp4
final_programme_asia2023.pdf
First-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC).mp4
First-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC).pdf
GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Breakthrough evolution in treatment landscape for solid tumors with ICIs.mp4
GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors General Q&A and closing.mp4
GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Key considerations in advanced_recurrent treatment of EC.mp4
GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Novel checkpoint combinations for advanced NSCLC.mp4
GSK – Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors Perspective on single-agent PD-1 blockade in dMMR CRC_solid tumors.mp4
Immunotherapy in nasopharyngeal carcinoma Biomarkers beyond PDL1.mp4
Immunotherapy in nasopharyngeal carcinoma Biomarkers beyond PDL1.pdf
Immunotherapy in nasopharyngeal carcinoma Q&A and discussion.mp4
Implication of lymphoma classification in 2023 Pathology aggressive B cell lymphomas.mp4
Implication of lymphoma classification in 2023 Pathology aggressive B cell lymphomas.pdf
Implication of lymphoma classification in 2023 Q&A and discussion.mp4
Implication of lymphoma classification in 2023 T cell lymphomas.mp4
Implication of lymphoma classification in 2023 T cell lymphomas.pdf
Implication of lymphoma classification in 2023 Treatment of aggressive B cell lymphomas.mp4
Implication of lymphoma classification in 2023 Treatment of aggressive B cell lymphomas.pdf
Implication of lymphoma classification in 2023 Treatment of T cell lymphomas.mp4
Implication of lymphoma classification in 2023 Treatment of T cell lymphomas.pdf
Improving outcomes in high-risk genitourinary cancers Adjuvant and salvage radiation in prostate cancer.mp4
Improving outcomes in high-risk genitourinary cancers Adjuvant and salvage radiation in prostate cancer.pdf
Improving outcomes in high-risk genitourinary cancers How to manage the conflicting adjuvant data in renal cell carcinoma (RCC).mp4
Improving outcomes in high-risk genitourinary cancers How to manage the conflicting adjuvant data in renal cell carcinoma (RCC).pdf
Improving outcomes in high-risk genitourinary cancers Perioperative management of high-risk urothelial cancer.mp4
Improving outcomes in high-risk genitourinary cancers Perioperative management of high-risk urothelial cancer.pdf
Improving outcomes in high-risk genitourinary cancers Q&A and discussion.mp4
Improving outcomes in high-risk genitourinary cancers Updates on adjuvant therapy for testicular cancer.mp4
Improving outcomes in high-risk genitourinary cancers Updates on adjuvant therapy for testicular cancer.pdf
Improving outcomes in high-risk genitourinary cancers Updates on penile cancer management.mp4
Improving outcomes in high-risk genitourinary cancers Updates on penile cancer management.pdf
In collaboration with AACR Early detection of cancer Emerging multi-cancer detection technologies in liquid biopsies.mp4
In collaboration with AACR Early detection of cancer Emerging multi-cancer detection technologies in liquid biopsies.pdf
In collaboration with AACR Early detection of cancer Genomic technologies for cancer risk prognostication and early detection.mp4
In collaboration with AACR Early detection of cancer Genomic technologies for cancer risk prognostication and early detection.pdf
In collaboration with AACR Early detection of cancer Novel metabolic imaging approaches for early cancer detection.mp4
In collaboration with AACR Early detection of cancer Novel metabolic imaging approaches for early cancer detection.pdf
In collaboration with AACR Early detection of cancer Novel study design and analysis for integrating multi-omics technologies for early detection of cancer.mp4
In collaboration with AACR Early detection of cancer Novel study design and analysis for integrating multi-omics technologies for early detection of cancer.pdf
In collaboration with AACR Early detection of cancer Q&A and discussion.mp4
In collaboration with AACR- Targeting the kinome Optimising combos of kinase inhibitors with other targeted agents.mp4
In collaboration with AACR- Targeting the kinome Optimising combos of kinase inhibitors with other targeted agents.pdf
In collaboration with AACR- Targeting the kinome Optimising dose selection in phase I trials.mp4
In collaboration with AACR- Targeting the kinome Optimising dose selection in phase I trials.pdf
In collaboration with AACR- Targeting the kinome Progress in preclinical development of targets and inhibitors.mp4
In collaboration with AACR- Targeting the kinome Progress in preclinical development of targets and inhibitors.pdf
In collaboration with AACR- Targeting the kinome Q&A and discussion.mp4
In collaboration with AACR- Targeting the kinome Selecting driver kinases in cell biology.mp4
In collaboration with AACR- Targeting the kinome Selecting driver kinases in cell biology.pdf
ini oral session Genitourinary tumours Invited Discussant 210MO and 211MO.mp4
ini oral session Genitourinary tumours Invited Discussant 210MO and 211MO.pdf
Latest updates in drug development New antibody drug conjugate (ADC) targets on the horizon.mp4
Latest updates in drug development New antibody drug conjugate (ADC) targets on the horizon.pdf
Latest updates in drug development New therapies targeting RAS-RAF signalling in solid tumours.mp4
Latest updates in drug development New therapies targeting RAS-RAF signalling in solid tumours.pdf
Latest updates in drug development Q&A and discussion.mp4
Learnings from Europe- Policy options Conclusions- How to transfer these solutions to Asia.mp4
Learnings from Europe- Policy options Conclusions- How to transfer these solutions to Asia.pdf
Learnings from Europe- Policy options Screening.mp4
Learnings from Europe- Policy options Screening.pdf
Learnings from Europe- Policy options Setting the scene- EU’s Beating Cancer Plan & overview of cancer incidence in the Asia-Pacific region.mp4
Learnings from Europe- Policy options Setting the scene- EU’s Beating Cancer Plan & overview of cancer incidence in the Asia-Pacific region.pdf
Learnings from Europe- Policy options Tobacco cessation lifestyle changes.mp4
Learnings from Europe- Policy options Tobacco cessation lifestyle changes.pdf
Levelling up Reducing inequalities in outcomes Clinical Practice Guidelines (CPG) as tools to reduce inequities in the AP region.mp4
Levelling up Reducing inequalities in outcomes Clinical Practice Guidelines (CPG) as tools to reduce inequities in the AP region.pdf
Levelling up Reducing inequalities in outcomes Inequities in access to standardsÿ of care in the AP region.mp4
Levelling up Reducing inequalities in outcomes Inequities in access to standardsÿ of care in the AP region.pdf
Levelling up Reducing inequalities in outcomes Measuring inequities in a single country.mp4
Levelling up Reducing inequalities in outcomes Measuring inequities in a single country.pdf
Levelling up Reducing inequalities in outcomes Setting the scene- Overview of key inequalities in theÿAsia-Pacific (AP) region and worldwide.pdf
Levelling up Reducing inequalities in outcomes The strategies of ERN to reduce inequities in EU (example of Genturis or Euracan).mp4
Levelling up Reducing inequalities in outcomes The strategies of ERN to reduce inequities in EU (example of Genturis or Euracan).pdf
Leveraging the molecular biology Enhancing immunotherapy responsiveness in squamous versus adenocarcinoma based on molecular biology (focus on primarily esophageal cancer).mp4
Leveraging the molecular biology Enhancing immunotherapy responsiveness in squamous versus adenocarcinoma based on molecular biology (focus on primarily esophageal cancer).pdf
Leveraging the molecular biology Immunotherapy in microsatellite stable (MSS) luminal gastrointestinal cancers.mp4
Leveraging the molecular biology Immunotherapy in microsatellite stable (MSS) luminal gastrointestinal cancers.pdf
Leveraging the molecular biology Leveraging the molecular biology of hepatocellular carcinoma (HCC) in optimising response to immunotherapy.mp4
Leveraging the molecular biology Leveraging the molecular biology of hepatocellular carcinoma (HCC) in optimising response to immunotherapy.pdf
Leveraging the molecular biology Q&A and discussion.mp4
Management of central nervous system Emerging systemic therapy options for CNS disease in HER2+ metastatic breast cancer.mp4
Management of central nervous system Emerging systemic therapy options for CNS disease in HER2+ metastatic breast cancer.pdf
Management of central nervous system Imaging modalities to diagnose and assess CNS disease in metastatic breast cancer- Which to choose and when.mp4
Management of central nervous system Imaging modalities to diagnose and assess CNS disease in metastatic breast cancer- Which to choose and when.pdf
Management of central nervous system Presentation of case condition.mp4
Management of central nervous system Presentation of case condition.pdf
Management of central nervous system Q&A and discussion.mp4
Management of central nervous system State of the art locoregional therapy for CNS metastases in metastatic HER2+ breast cancer.mp4
Management of central nervous system State of the art locoregional therapy for CNS metastases in metastatic HER2+ breast cancer.pdf
Mini oral session 1 Gastrointestinal tumours Invited Discussant 132MO and 133MO.mp4
Mini oral session 1 Gastrointestinal tumours Invited Discussant 132MO and 133MO.pdf
Mini oral session 1 Gastrointestinal tumours Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC).mp4
Mini oral session 1 Gastrointestinal tumours Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC).pdf
Mini oral session 1 Gastrointestinal tumours Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem cis) compared with gem cis.mp4
Mini oral session 1 Gastrointestinal tumours Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem cis) compared with gem cis.pdf
Mini oral session 1 Gastrointestinal tumours Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H).mp4
Mini oral session 1 Gastrointestinal tumours Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H).pdf
Mini oral session 1 Gastrointestinal tumours Q&A and discussion 1.mp4
Mini oral session 1 Gastrointestinal tumours Q&A and discussion 2.mp4
Mini oral session 1 Gastrointestinal tumours Q&A and discussion 3.mp4
Mini oral session 1 Gastrointestinal tumours Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated.mp4
Mini oral session 1 Gastrointestinal tumours Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated.pdf
Mini oral session 1 Gastrointestinal tumours Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS.mp4
Mini oral session 1 Gastrointestinal tumours Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS.pdf
Mini oral session 1 Gastrointestinal tumours Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2.mp4
Mini oral session 1 Gastrointestinal tumours Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2.pdf
Mini oral session 1 Thoracic cancer Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic.mp4
Mini oral session 1 Thoracic cancer Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced metastatic.pdf
Mini oral session 1 Thoracic cancer Dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous.mp4
Mini oral session 1 Thoracic cancer Dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous.pdf
Mini oral session 1 Thoracic cancer Invited Discussant 508MO, 509MO and 510MO.mp4
Mini oral session 1 Thoracic cancer Invited Discussant 508MO, 509MO and 510MO.pdf
Mini oral session 1 Thoracic cancer Invited Discussant LBA13 and 511MO.mp4
Mini oral session 1 Thoracic cancer Invited Discussant LBA13 and 511MO.pdf
Mini oral session 1 Thoracic cancer Q&A and discussion.mp4
Mini oral session 1 Thoracic cancer Tarlatamab for patients (pts) with previously treated small cell lung cance.mp4
Mini oral session 1 Thoracic cancer Tarlatamab for patients (pts) with previously treated small cell lung cance.pdf
Mini oral session 1 Thoracic cancer Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2.mp4
Mini oral session 1 Thoracic cancer Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2.pdf
Mini oral session 2 Gastrointestinal tumours Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients.mp4
Mini oral session 2 Gastrointestinal tumours Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients.pdf
Mini oral session 2 Gastrointestinal tumours Invited Discussant 134MO, 135MO and 136MO.mp4
Mini oral session 2 Gastrointestinal tumours Invited Discussant 134MO, 135MO and 136MO.pdf
Mini oral session 2 Gastrointestinal tumours Invited Discussant 138MO and 139MO.mp4
Mini oral session 2 Gastrointestinal tumours Invited Discussant 138MO and 139MO.pdf
Mini oral session 2 Gastrointestinal tumours Q&A and discussion 1.mp4
Mini oral session 2 Gastrointestinal tumours Q&A and discussion 2.mp4
Mini oral session 2 Gastrointestinal tumours Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line.mp4
Mini oral session 2 Gastrointestinal tumours Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line.pdf
Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab.mp4
Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab.pdf
Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab.mp4
Mini oral session 2 Gastrointestinal tumours Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab.pdf
Mini oral session 2 Thoracic cancer Acquired mechanisms of resistance to first-line (1L) osimertinib.mp4
Mini oral session 2 Thoracic cancer Acquired mechanisms of resistance to first-line (1L) osimertinib.pdf
Mini oral session 2 Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian.mp4
Mini oral session 2 Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian.pdf
Mini oral session 2 Thoracic cancer Efficacy and safety of MCLA-129, an anti-EGFRc-MET bispecific antibody.mp4
Mini oral session 2 Thoracic cancer Efficacy and safety of MCLA-129, an anti-EGFRc-MET bispecific antibody.pdf
Mini oral session 2 Thoracic cancer Final overall survival (OS) results of befotertinib in patients with pretreated EGFR.mp4
Mini oral session 2 Thoracic cancer Final overall survival (OS) results of befotertinib in patients with pretreated EGFR.pdf
Mini oral session 2 Thoracic cancer FLAURA2 Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC.mp4
Mini oral session 2 Thoracic cancer FLAURA2 Safety and CNS outcomes of first-line (1L) osimertinib (osi) ñ chemotherapy (CTx) in EGFRm advanced NSCLC.pdf
Mini oral session 2 Thoracic cancer Invited Discussant 490MO and 518MO.mp4
Mini oral session 2 Thoracic cancer Invited Discussant 490MO and 518MO.pdf
Mini oral session 2 Thoracic cancer Invited Discussant 512MO, 513MO and 514MO.mp4
Mini oral session 2 Thoracic cancer Invited Discussant 512MO, 513MO and 514MO.pdf
Mini oral session 2 Thoracic cancer Invited Discussant LBA9, 515MO and 516MO.mp4
Mini oral session 2 Thoracic cancer Invited Discussant LBA9, 515MO and 516MO.pdf
Mini oral session 2 Thoracic cancer Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients.mp4
Mini oral session 2 Thoracic cancer Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients.pdf
Mini oral session 2 Thoracic cancer Q&A and discussion 1.mp4
Mini oral session 2 Thoracic cancer Q&A and discussion 2.mp4
Mini oral session 2 Thoracic cancer Q&A and discussion 3.mp4
Mini oral session 2 Thoracic cancerPatient-reported outcomes of first-line selpercatinib versus chemotherapy.mp4
Mini oral session 2 Thoracic cancerPatient-reported outcomes of first-line selpercatinib versus chemotherapy.pdf
Mini oral session Breast cancer A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic.mp4
Mini oral session Breast cancer A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic.pdf
Mini oral session Breast cancer Analytical and clinical validation of a ctDNA-based assay for multi-cancer detection.mp4
Mini oral session Breast cancer Analytical and clinical validation of a ctDNA-based assay for multi-cancer detection.pdf
Mini oral session Breast cancer First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT).mp4
Mini oral session Breast cancer First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT).pdf
Mini oral session Breast cancer Image biomarker discovery from DCE-MRI for identifying responders.mp4
Mini oral session Breast cancer Image biomarker discovery from DCE-MRI for identifying responders.pdf
Mini oral session Breast cancer Invited Discussant LBA3, LBA6 and 57MO.pdf
Mini oral session Breast cancer Invited Discussant one LBA2, 1MO and 56MO.mp4
Mini oral session Breast cancer Invited Discussant one LBA2, 1MO and 56MO.pdf
Mini oral session Breast cancer Landscape of ESR1 mutations in advanced breast cancer using circulating tumor DNA.mp4
Mini oral session Breast cancer Landscape of ESR1 mutations in advanced breast cancer using circulating tumor DNA.pdf
Mini oral session Breast cancer Multimodal data fusion enhanced precision neoadjuvant chemotherapy in breast cancer.mp4
Mini oral session Breast cancer Multimodal data fusion enhanced precision neoadjuvant chemotherapy in breast cancer.pdf
Mini oral session Breast cancer Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy.mp4
Mini oral session Breast cancer Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy.pdf
Mini oral session Breast cancer Q&A and discussion 1.mp4
Mini oral session Breast cancer Q&A and discussion 2.mp4
Mini oral session Breast cancer Q&A and discussion 3.mp4
Mini oral session Genitourinary tumours 1.mp4
Mini oral session Genitourinary tumours 2.mp4
Mini oral session Genitourinary tumours 3.mp4
Mini oral session Genitourinary tumours Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume.mp4
Mini oral session Genitourinary tumours Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume.pdf
Mini oral session Genitourinary tumours Enzalutamide versus abiraterone plus prednisolone for Japanese non-metastatic.mp4
Mini oral session Genitourinary tumours Enzalutamide versus abiraterone plus prednisolone for Japanese non-metastatic.pdf
Mini oral session Genitourinary tumours EV-302KEYNOTE-A39- Open-label, randomized phase III study of enfortumab.mp4
Mini oral session Genitourinary tumours EV-302KEYNOTE-A39- Open-label, randomized phase III study of enfortumab.pdf
Mini oral session Genitourinary tumours Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC).mp4
Mini oral session Genitourinary tumours Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC).pdf
Mini oral session Genitourinary tumours Invited Discussant 258MO and 260MO.mp4
Mini oral session Genitourinary tumours Invited Discussant 258MO and 260MO.pdf
Mini oral session Genitourinary tumours Low dose nivolumab with TKI in mRCC- Dosing strategies, de-escalation and survival among self-paying patients in India.mp4
Mini oral session Genitourinary tumours Low dose nivolumab with TKI in mRCC- Dosing strategies, de-escalation and survival among self-paying patients in India.pdf
Mini oral session Genitourinary tumours Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP).mp4
Mini oral session Genitourinary tumours Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP).pdf
Mini oral session Haematological malignancies Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients.mp4
Mini oral session Haematological malignancies Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients.pdf
Mini oral session Haematological malignancies HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis.mp4
Mini oral session Haematological malignancies HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis.pdf
Mini oral session Haematological malignancies Invited Discussant 328MO, 329MO and 330MO.mp4
Mini oral session Haematological malignancies Invited Discussant 328MO, 329MO and 330MO.pdf
Mini oral session Haematological malignancies Invited Discussant 331MO and 332MO.mp4
Mini oral session Haematological malignancies Invited Discussant 331MO and 332MO.pdf
Mini oral session Haematological malignancies Invited Discussant 333MO and 334MO.mp4
Mini oral session Haematological malignancies Invited Discussant 333MO and 334MO.pdf
Mini oral session Haematological malignancies Invited Discussant 335MO and 336MO.mp4
Mini oral session Haematological malignancies Invited Discussant 335MO and 336MO.pdf
Mini oral session Haematological malignancies Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies.mp4
Mini oral session Haematological malignancies Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies.pdf
Mini oral session Haematological malignancies Q&A and discussion 1.mp4
Mini oral session Haematological malignancies Q&A and discussion 2.mp4
Mini oral session Haematological malignancies Q&A and discussion 3.mp4
Mini oral session Haematological malignancies Real-world outcomes of diffuse large B cell lymphoma treated.mp4
Mini oral session Haematological malignancies Real-world outcomes of diffuse large B cell lymphoma treated.pdf
Mini oral session Haematological malignancies Treatment patterns in patients with mantle cell lymphoma.mp4
Mini oral session Haematological malignancies Treatment patterns in patients with mantle cell lymphoma.pdf
Mini oral session Head and neck cancer Characterizing the role of NSD family of histone methyltransferases in the head and neck squamous cell carcinoma tumor immune microenvironment.mp4
Mini oral session Head and neck cancer Characterizing the role of NSD family of histone methyltransferases in the head and neck squamous cell carcinoma tumor immune microenvironment.pdf
Mini oral session Head and neck cancer Comparison of long-term quality of life between survivors of adolescent and adult nasopharyngeal carcinoma.mp4
Mini oral session Head and neck cancer Comparison of long-term quality of life between survivors of adolescent and adult nasopharyngeal carcinoma.pdf
Mini oral session Head and neck cancer Invited Discussant 357MO and 358MO.mp4
Mini oral session Head and neck cancer Invited Discussant 357MO and 358MO.pdf
Mini oral session Head and neck cancer Invited Discussant 359MO, 360MO and 361MO.mp4
Mini oral session Head and neck cancer Invited Discussant 359MO, 360MO and 361MO.pdf
Mini oral session Head and neck cancer Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment.mp4
Mini oral session Head and neck cancer Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment.pdf
Mini oral session Head and neck cancer Phase I dose-escalation study of nab-paclitaxel combined with cisplatin.mp4
Mini oral session Head and neck cancer Phase I dose-escalation study of nab-paclitaxel combined with cisplatin.pdf
Mini oral session Head and neck cancer Q&A and discussion 1.mp4
Mini oral session Head and neck cancer Q&A and discussion 2.mp4
Mini oral session Head and neck cancer Quality-adjusted life-year and life-year estimates for patients.mp4
Mini oral session Head and neck cancer Quality-adjusted life-year and life-year estimates for patients.pdf
Mini oral session Supportive and palliative care Barriers and facilitators of home-based exercise intervention.mp4
Mini oral session Supportive and palliative care Barriers and facilitators of home-based exercise intervention.pdf
Mini oral session Supportive and palliative care Cost-effective evaluation of homemade diet recipe in head and neck cancer.pdf
Mini oral session Supportive and palliative care Impact of Nada yoga music therapy on anxiety and quality of life in ovarian cancer patients.mp4
Mini oral session Supportive and palliative care Impact of Nada yoga music therapy on anxiety and quality of life in ovarian cancer patients.pdf
Mini oral session Supportive and palliative care Increased eosinophil is a universal biomarker for immune-related.mp4
Mini oral session Supportive and palliative care Increased eosinophil is a universal biomarker for immune-related.pdf
Mini oral session Supportive and palliative care Invited Discussant 394MO and 395MO.mp4
Mini oral session Supportive and palliative care Invited Discussant 394MO and 395MO.pdf
Mini oral session Supportive and palliative care Invited Discussant 433MO and 434MO.mp4
Mini oral session Supportive and palliative care Invited Discussant 433MO and 434MO.pdf
Mini oral session Supportive and palliative care Prognostic models for survival predictions in advanced cancer patients- A systematic review and meta-analysis.mp4
Mini oral session Supportive and palliative care Prognostic models for survival predictions in advanced cancer patients- A systematic review and meta-analysis.pdf
Mini oral session Supportive and palliative care Q&A and discussion 1.mp4
Mini oral session Supportive and palliative care Q&A and discussion 2.mp4
Mini oral session Supportive and palliative care Q&A and discussion 3.mp4
Mini oral session Supportive and palliative care Structure of QOLLTI-F in Chinese-speaking carers of palliative care patients.mp4
Mini oral session Supportive and palliative care Structure of QOLLTI-F in Chinese-speaking carers of palliative care patients.pdf
Mini oral session Supportive and palliative care Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy.mp4
Mini oral session Supportive and palliative care Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy.pdf
Mixed Proffered paper and Mini oral session A first-in-human, open-label, dose-escalation study of ERK12.mp4
Mixed Proffered paper and Mini oral session A first-in-human, open-label, dose-escalation study of ERK12.pdf
Mixed Proffered paper and Mini oral session Efficacy and safety findings from MANTRA.mp4
Mixed Proffered paper and Mini oral session Efficacy and safety findings from MANTRA.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Determining the maximum tolerated dose of paclitaxel combined.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Determining the maximum tolerated dose of paclitaxel combined.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy and safety of topical sintilimab administration.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy and safety of topical sintilimab administration.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy of low dose nivolumab in recurrent metastatic cervical cancer.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Efficacy of low dose nivolumab in recurrent metastatic cervical cancer.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts).mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts).pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers InnovaTV 301ENGOT-cx12GOG-3057.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers InnovaTV 301ENGOT-cx12GOG-3057.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 285O, 286MO and 287MO.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 285O, 286MO and 287MO.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 288MO, 289MO and 290MO.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant 288MO, 289MO and 290MO.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant LBA8 and 291MO.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Invited Discussant LBA8 and 291MO.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Preliminary efficacy of pembrolizumab plus lenvatinib.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Preliminary efficacy of pembrolizumab plus lenvatinib.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Prevalence of homologous recombination deficiency in ovarian, primary peritoneal.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Prevalence of homologous recombination deficiency in ovarian, primary peritoneal.pdf
Mixed Proffered paper and Mini oral session Gynaecological cancers Q&A and discussion 1.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Q&A and discussion 2.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Q&A and discussion 3.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Real-world experience with maintenance PARP inhibitor plus minus bevacizumab.mp4
Mixed Proffered paper and Mini oral session Gynaecological cancers Real-world experience with maintenance PARP inhibitor plus minus bevacizumab.pdf
Mixed Proffered paper and Mini oral session Invited Discussant 402O.mp4
Mixed Proffered paper and Mini oral session Invited Discussant 402O.pdf
Mixed Proffered paper and Mini oral session Invited Discussant 404MO and 405MO.mp4
Mixed Proffered paper and Mini oral session Invited Discussant 404MO and 405MO.pdf
Mixed Proffered paper and Mini oral session Invited Discussant 74MO, 75MO, 76MO and 77MO.mp4
Mixed Proffered paper and Mini oral session Invited Discussant 74MO, 75MO, 76MO and 77MO.pdf
Mixed Proffered paper and Mini oral session Pan-cancer analysis of 4-1BB transcriptome expression.mp4
Mixed Proffered paper and Mini oral session Pan-cancer analysis of 4-1BB transcriptome expression.pdf
Mixed Proffered paper and Mini oral session Phase I trial of the DLL3CD3 IgG-like T cell.mp4
Mixed Proffered paper and Mini oral session Phase I trial of the DLL3CD3 IgG-like T cell.pdf
Mixed Proffered paper and Mini oral session Q&A and discussion 1.mp4
Mixed Proffered paper and Mini oral session Q&A and discussion 2.mp4
Mixed Proffered paper and Mini oral session Q&A and discussion 3.mp4
Mixed Proffered paper and Mini oral session Tertiary lymphoid structures localization and maturation heterogeneities.mp4
Mixed Proffered paper and Mini oral session Tertiary lymphoid structures localization and maturation heterogeneities.pdf
Mixed Proffered paper and Mini oral session Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts).mp4
Mixed Proffered paper and Mini oral session Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts).pdf
New treatment options for sarcomas Q&A and discussion.mp4
New treatment options for sarcomas What is new in treatments for liposarcoma.mp4
New treatment options for sarcomas What is new in treatments for liposarcoma.pdf
New treatment options for sarcomas What is new in treatments for tenosynovial giant cell tumor (TGCT).mp4
New treatment options for sarcomas What is new in treatments for tenosynovial giant cell tumor (TGCT).pdf
New treatment options for sarcomas What is new in treatments for ultra-rare sarcomas.mp4
New treatment options for sarcomas What is new in treatments for ultra-rare sarcomas.pdf
Non-small cell lung cancer Mechanisms of resistance to immunotherapy.mp4
Non-small cell lung cancer Mechanisms of resistance to immunotherapy.pdf
Non-small cell lung cancer Q&A and discussion.mp4
Non-small cell lung cancer Role of local treatment.mp4
Non-small cell lung cancer Role of local treatment.pdf
Novel approaches and challenges for treatment of head and neck cancer Boron neutron capture therapy (BNCT) as an emerging tool to treat head and neck cancer.mp4
Novel approaches and challenges for treatment of head and neck cancer Boron neutron capture therapy (BNCT) as an emerging tool to treat head and neck cancer.pdf
Novel approaches and challenges for treatment of head and neck cancer Challenges to overcoming radio-resistance in head and neck cancer.mp4
Novel approaches and challenges for treatment of head and neck cancer Challenges to overcoming radio-resistance in head and neck cancer.pdf
Novel approaches and challenges for treatment of head and neck cancer Novel immunotherapy approaches for head and neck cancer.mp4
Novel approaches and challenges for treatment of head and neck cancer Novel immunotherapy approaches for head and neck cancer.pdf
Novel approaches and challenges for treatment of head and neck cancer Q&A and discussion.mp4
Novel approaches and challenges for treatment of head and neck cancer Tumour biology and clinical outcomes in head and neck cancer- Does gender matter.mp4
Novel approaches and challenges for treatment of head and neck cancer Tumour biology and clinical outcomes in head and neck cancer- Does gender matter.pdf
Novel therapies shaping the treatment landscape of gynecologic malignancies ADCs in gynaecological malignancies.mp4
Novel therapies shaping the treatment landscape of gynecologic malignancies ADCs in gynaecological malignancies.pdf
Novel therapies shaping the treatment landscape of gynecologic malignancies Immunotherapy in gynecologic malignancies- Current role and future prospects.mp4
Novel therapies shaping the treatment landscape of gynecologic malignancies Immunotherapy in gynecologic malignancies- Current role and future prospects.pdf
Novel therapies shaping the treatment landscape of gynecologic malignancies Managing the toxicities of novel compounds.mp4
Novel therapies shaping the treatment landscape of gynecologic malignancies Managing the toxicities of novel compounds.pdf
Novel therapies shaping the treatment landscape of gynecologic malignancies Predictive biomarkers of response to immunotherapy and ADC in gynecological cancer.mp4
Novel therapies shaping the treatment landscape of gynecologic malignancies Predictive biomarkers of response to immunotherapy and ADC in gynecological cancer.pdf
Novel therapies shaping the treatment landscape of gynecologic malignancies Q&A and discussion.mp4
Oncogene-driven non-small cell lung cancer HER2 mutation.mp4
Oncogene-driven non-small cell lung cancer HER2 mutation.pdf
Oncogene-driven non-small cell lung cancer KRAS.mp4
Oncogene-driven non-small cell lung cancer KRAS.pdf
Oncogene-driven non-small cell lung cancer New fusions RET, NTRK, ROS1.mp4
Oncogene-driven non-small cell lung cancer New fusions RET, NTRK, ROS1.pdf
Oncogene-driven non-small cell lung cancer Q&A and discussion.mp4
Opening session and Keynote lecture Scientific Co-Chairs- Programme and key highlights of the meeting.mp4
Opening session and Keynote lecture Token of Appreciation Endorsing society representatives.mp4
Opening session and Keynote lecture Welcome address by the ESMO President, Prof. Andr‚s Cervantes.mp4
Opening session and Keynote lecture Welcome address by the ESMO President, Prof. Andr‚s Cervantes.pdf
Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Early breast cancer.mp4
Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Early breast cancer.pdf
Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Gastric cancer.mp4
Practicing oncology across the globe A clinical case and analysis of its management according to the recent PAGA- Gastric cancer.pdf
Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Early breast cancer.mp4
Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Early breast cancer.pdf
Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Gastric cancer.mp4
Practicing oncology across the globe Differences between the parent guideline (CPG) and the PAGA Gastric cancer.pdf
Practicing oncology across the globe Q&A and discussion 1.mp4
Practicing oncology across the globe Q&A and discussion 2.mp4
Presidential Symposium Asian subgroup analysis of the THOR phase III study- Erdafitinib versus chemotherapy.mp4
Presidential Symposium Asian subgroup analysis of the THOR phase III study- Erdafitinib versus chemotherapy.pdf
Presidential Symposium Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy.mp4
Presidential Symposium Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy.pdf
Presidential Symposium EXCLAIM-2 Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy.mp4
Presidential Symposium EXCLAIM-2 Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy.pdf
Presidential Symposium Invited Discussant 208O.mp4
Presidential Symposium Invited Discussant 208O.pdf
Presidential Symposium Invited Discussant 507O.mp4
Presidential Symposium Invited Discussant 507O.pdf
Presidential Symposium Invited Discussant LBA1.mp4
Presidential Symposium Invited Discussant LBA1.pdf
Presidential Symposium Q&A and discussion 1.mp4
Presidential Symposium Q&A and discussion 2.mp4
Presidential Symposium Q&A and discussion 3.mp4
Proffered Paper session Breast cancer Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor.mp4
Proffered Paper session Breast cancer Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor.pdf
Proffered Paper session Breast cancer Invited Discussant one LBA4 and 54O.mp4
Proffered Paper session Breast cancer Invited Discussant one LBA4 and 54O.pdf
Proffered Paper session Breast cancer Invited Discussant one LBA5 and 55O.mp4
Proffered Paper session Breast cancer Invited Discussant one LBA5 and 55O.pdf
Proffered Paper session Breast cancer Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER+) breast cancer.mp4
Proffered Paper session Breast cancer Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER+) breast cancer.pdf
Proffered Paper session Breast cancer Q&A and discussion 1.mp4
Proffered Paper session Breast cancer Q&A and discussion 2.mp4
Proffered Paper session Breast cancer Sacituzumab govitecan (SG) vs treatment of physician’s choice.mp4
Proffered Paper session Breast cancer Sacituzumab govitecan (SG) vs treatment of physician’s choice.pdf
Proffered Paper session Gastrointestinal tumours Invited Discussant – surgical perspective of 129O and 130O.mp4
Proffered Paper session Gastrointestinal tumours Invited Discussant – surgical perspective of 129O and 130O.pdf
Proffered Paper session Gastrointestinal tumours Invited Discussant 129O and 130O.mp4
Proffered Paper session Gastrointestinal tumours Invited Discussant 129O and 130O.pdf
Proffered Paper session Gastrointestinal tumours Invited Discussant 89O.mp4
Proffered Paper session Gastrointestinal tumours Invited Discussant 89O.pdf
Proffered Paper session Gastrointestinal tumours Long-term outcomes of intraoperative chemotherapy with 5-FU.mp4
Proffered Paper session Gastrointestinal tumours Long-term outcomes of intraoperative chemotherapy with 5-FU.pdf
Proffered Paper session Gastrointestinal tumours Pathological complete response (pCR) to durvalumab plus 5-fluorouracil.mp4
Proffered Paper session Gastrointestinal tumours Pathological complete response (pCR) to durvalumab plus 5-fluorouracil.pdf
Proffered Paper session Gastrointestinal tumours Q&A and discussion 1.mp4
Proffered Paper session Gastrointestinal tumours Q&A and discussion 2.mp4
Proffered Paper session Gastrointestinal tumours The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811.mp4
Proffered Paper session Gastrointestinal tumours The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811.pdf
Proffered Paper session Genitourinary tumours Association of enzalutamide (ENZA) duration of treatment.mp4
Proffered Paper session Genitourinary tumours Association of enzalutamide (ENZA) duration of treatment.pdf
Proffered Paper session Genitourinary tumours Darolutamide (DARO) in combination with androgen-deprivation therapy.mp4
Proffered Paper session Genitourinary tumours Darolutamide (DARO) in combination with androgen-deprivation therapy.pdf
Proffered Paper session Genitourinary tumours Invited Discussant 255O, 256O and 257O.mp4
Proffered Paper session Genitourinary tumours Invited Discussant 255O, 256O and 257O.pdf
Proffered Paper session Genitourinary tumours Prostate-specific antigen response to different real-world treatments.mp4
Proffered Paper session Genitourinary tumours Prostate-specific antigen response to different real-world treatments.pdf
Proffered Paper session Genitourinary tumours Q&A and discussion.mp4
Proffered Paper session Head and neck cancer A phase Ib II study of nanatinostat (Nstat).mp4
Proffered Paper session Head and neck cancer A phase Ib II study of nanatinostat (Nstat).pdf
Proffered Paper session Head and neck cancer Artificial intelligence-powered spatial analysis of tumor microenvironment.mp4
Proffered Paper session Head and neck cancer Artificial intelligence-powered spatial analysis of tumor microenvironment.pdf
Proffered Paper session Head and neck cancer Construction of an immune-related adverse events prediction model.mp4
Proffered Paper session Head and neck cancer Construction of an immune-related adverse events prediction model.pdf
Proffered Paper session Head and neck cancer Efficacy and safety of ENZ-124 versus innovator cetuximab.mp4
Proffered Paper session Head and neck cancer Efficacy and safety of ENZ-124 versus innovator cetuximab.pdf
Proffered Paper session Head and neck cancer Invited Discussant 353O and 354O.mp4
Proffered Paper session Head and neck cancer Invited Discussant 353O and 354O.pdf
Proffered Paper session Head and neck cancer Invited Discussant 355O and 356O.mp4
Proffered Paper session Head and neck cancer Invited Discussant 355O and 356O.pdf
Proffered Paper session Head and neck cancer Q&A and discussion 1.mp4
Proffered Paper session Head and neck cancer Q&A and discussion 2.mp4
Proffered Paper session Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy among A MARIPOSA-2 subgroup analysis.mp4
Proffered Paper session Thoracic cancer Amivantamab plus chemotherapy vs chemotherapy among A MARIPOSA-2 subgroup analysis.pdf
Proffered Paper session Thoracic cancer Amivantamab plus lazertinib vs osimertinib as first-line treatment among.mp4
Proffered Paper session Thoracic cancer Amivantamab plus lazertinib vs osimertinib as first-line treatment among.pdf
Proffered Paper session Thoracic cancer Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor.mp4
Proffered Paper session Thoracic cancer Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor.pdf
Proffered Paper session Thoracic cancer Invited Discussant LBA10 and LBA11.mp4
Proffered Paper session Thoracic cancer Invited Discussant LBA10 and LBA11.pdf
Proffered Paper session Thoracic cancer Invited Discussant LBA12.mp4
Proffered Paper session Thoracic cancer Invited Discussant LBA12.pdf
Proffered Paper session Thoracic cancer Q&A and discussion 1.mp4
Proffered Paper session Thoracic cancer Q&A and discussion 2.mp4
Radiation oncology session 1 Clinical case 1.mp4
Radiation oncology session 1 Clinical case 1.pdf
Radiation oncology session 1 Clinical case 2.pdf
Radiation oncology session 1 General discussion and conclusions.mp4
Radiation oncology session 1 Real world consensus status on oligometastasis management- Korean caregivers perspective.mp4
Radiation oncology session 1 Real world consensus status on oligometastasis management- Korean caregivers perspective.pdf
Radiation oncology session 1 Role of new generation TKIs vs SRS in metastatic NSCLC.mp4
Radiation oncology session 1 Role of new generation TKIs vs SRS in metastatic NSCLC.pdf
Radiation oncology session 1 Single or fractionated radiosurgery for oligomets What have we learnt from SAFRON trial experience.mp4
Radiation oncology session 1 Single or fractionated radiosurgery for oligomets What have we learnt from SAFRON trial experience.pdf
Radiation oncology session 2 Current status of SBRT in lung cancer.mp4
Radiation oncology session 2 Current status of SBRT in lung cancer.pdf
Radiation oncology session 2 General discussion and conclusions.mp4
Radiation oncology session 2 State of the art of radiotherapy in advanced prostate cancer.mp4
Radiation oncology session 2 State of the art of radiotherapy in advanced prostate cancer.pdf
Seagen What’s next for ADCs in oncology Advances in integrin targeting.mp4
Seagen What’s next for ADCs in oncology Multimodal immune targeting with ADCs.mp4
Seagen What’s next for ADCs in oncology Panel discussion, live Q&A, and conclusions.mp4
Seagen What’s next for ADCs in oncology State of the art and perspectives.mp4
Seagen What’s next for ADCs in oncology Welcome and introduction.mp4
Supporting shared decision making in face of uncertainty Advance care planning and serious illness conversations.mp4
Supporting shared decision making in face of uncertainty Advance care planning and serious illness conversations.pdf
Supporting shared decision making in face of uncertainty Q&A and discussion.mp4
Supporting shared decision making in face of uncertainty Supporting caregivers of patients with advanced cancer.mp4
Supporting shared decision making in face of uncertainty Supporting caregivers of patients with advanced cancer.pdf
Transition from hormone-sensitive to castration-resistant prostate cancer Introduction to the session and presentation of case condition.mp4
Transition from hormone-sensitive to castration-resistant prostate cancer Introduction to the session and presentation of case condition.pdf
Transition from hormone-sensitive to castration-resistant prostate cancer Pragmatic approach to treatment selection in metastatic castration-resistant prostate cancer (mCRPC).mp4
Transition from hormone-sensitive to castration-resistant prostate cancer Pragmatic approach to treatment selection in metastatic castration-resistant prostate cancer (mCRPC).pdf
Transition from hormone-sensitive to castration-resistant prostate cancer Progression of the case.mp4
Transition from hormone-sensitive to castration-resistant prostate cancer Progression of the case.pdf
Transition from hormone-sensitive to castration-resistant prostate cancer PSMA imaging and theranostics.mp4
Transition from hormone-sensitive to castration-resistant prostate cancer PSMA imaging and theranostics.pdf
Transition from hormone-sensitive to castration-resistant prostate cancer Q&A and discussion.mp4
Transition from hormone-sensitive to castration-resistant prostate cancer Use of PARP inhibitors in prostate cancer- Current data and future directions.mp4
Transition from hormone-sensitive to castration-resistant prostate cancer Use of PARP inhibitors in prostate cancer- Current data and future directions.pdf
Treatment optimisation in early triple negative breast cancer (TNBC) Optimal application of preoperative immunotherapy and management of residual disease.mp4
Treatment optimisation in early triple negative breast cancer (TNBC) Optimal application of preoperative immunotherapy and management of residual disease.pdf
Treatment optimisation in early triple negative breast cancer (TNBC) Q&A and discussion.mp4
Treatment optimisation in early triple negative breast cancer (TNBC) What is the optimal systemic treatment of stage 1 TNBC.mp4
Treatment optimisation in early triple negative breast cancer (TNBC) What is the optimal systemic treatment of stage 1 TNBC.pdf
What’s new in 2023 (Investigational immunotherapy) Genetically-engineered cellular therapies- Expanding indications.mp4
What’s new in 2023 (Investigational immunotherapy) Genetically-engineered cellular therapies- Expanding indications.pdf
What’s new in 2023 (Investigational immunotherapy) Q&A and discussion.mp4
What’s new in 2023 (Investigational immunotherapy) Vaccines for cancer treatment- Finally primetime.mp4
What’s new in 2023 (Investigational immunotherapy) Vaccines for cancer treatment- Finally primetime.pdf
What’s new in 2023 (Investigational immunotherapy) Why adjuvant when there is neoadjuvant.mp4
What’s new in 2023 (Investigational immunotherapy) Why adjuvant when there is neoadjuvant.pdf
Young Oncologists clinical cases discussion A Rare Case of Breast Cancer in A Postpartum Female with Reoccurrence of Breast Cancer During Pregnancy.mp4
Young Oncologists clinical cases discussion A Rare Case of Breast Cancer in A Postpartum Female with Reoccurrence of Breast Cancer During Pregnancy.pdf
Young Oncologists clinical cases discussion Chemotherapy-resistant epithelioid trophoblastic tumor successfully treated by immunotherapy.mp4
Young Oncologists clinical cases discussion Chemotherapy-resistant epithelioid trophoblastic tumor successfully treated by immunotherapy.pdf
Young Oncologists clinical cases discussion In-depth analysis of unknown NTRK1-fusion gene detected in DNA-based.mp4
Young Oncologists clinical cases discussion In-depth analysis of unknown NTRK1-fusion gene detected in DNA-based.pdf
Young Oncologists clinical cases discussion Invited Discussant YO16 and YO20.mp4
Young Oncologists clinical cases discussion Invited Discussant YO16 and YO20.pdf
Young Oncologists clinical cases discussion Invited Discussant YO2 and YO31.mp4
Young Oncologists clinical cases discussion Invited Discussant YO2 and YO31.pdf
Young Oncologists clinical cases discussion Invited Discussant YO5 and YO26.mp4
Young Oncologists clinical cases discussion Invited Discussant YO5 and YO26.pdf
Young Oncologists clinical cases discussion Q&A and discussion 1.mp4
Young Oncologists clinical cases discussion Q&A and discussion 2.mp4
Young Oncologists clinical cases discussion Q&A and discussion 3.mp4
Young Oncologists clinical cases discussion Solitary Cardiac Metastasis in BRAFV600E Mutation Colon Cancer.mp4
Young Oncologists clinical cases discussion Solitary Cardiac Metastasis in BRAFV600E Mutation Colon Cancer.pdf
Young Oncologists clinical cases discussion The efficacy and safety of aumolertinib plus alectinib in NSCLC patients haboring EGFR 19 Del.mp4
Young Oncologists clinical cases discussion The efficacy and safety of aumolertinib plus alectinib in NSCLC patients haboring EGFR 19 Del.pdf
Young Oncologists clinical cases discussion Their voices are louder than yours, doctor Unspoken challenges managing breast cancer.mp4
Young Oncologists clinical cases discussion Their voices are louder than yours, doctor Unspoken challenges managing breast cancer.pdf